Sividon Diagnostics GmbH
ASCO 2013: New data on breast cancer prognosis tests – EndoPredict and uPA/PAI-1 compared
Cologne/ Chicago – At the annual meeting of the «American Society of Clinical Oncology» (ASCO) in Chicago, new data from clinical practice on the breast cancer prognosis tests EndoPredict and uPA/PAI-1 were presented. Both tests can be used for risk assessment in breast cancer. Here the goal is to be able to provide a clear recommendation in favour of or against chemotherapy. In a comparative study at the Technical University of Munich, the influence on the final treatment decision was evaluated. «Our prospective study shows for the first time that with the more modern EndoPredict many more patients can be assigned to a low-risk group than with the older uPA/PAI-1 test», explains Prof. Dr. Marion Kiechle, Director of the Gynaecological Department of the Klinikum rechts der Isar, Technical University of Munich. «In addition, EndoPredict is easier to use, since no fresh tissue is needed, and it can be applied in a wider patient population.» Tumour samples from patients with hormone receptor-positive and Her2/neu-negative breast cancer were examined. The gene-based EPclin score was determined (37 % high risk, 63 % low risk), and when possible and appropriate, the level of uPA/PAI-1 was determined, too (63 % high risk, 37 % low risk). «The treatment decision was brought about mainly by the EPclin. Thanks to the test results, 44 percent of patients received no chemotherapy although this had initially been planned. In 5 percent it was precisely reverse; these patients received chemotherapy due to the increased risk identified by the EPclin», explains Prof. Kiechle. «All in all, we can say that the EndoPredict is the more versatile and powerful method for prognosis determination. It is easier to use in clinical practice and allows to spare another third of patients chemotherapy.» EndoPredict is a multigenic prognosis test developed specifically for breast cancer patients that has been clinically validated in three studies involving over 2,200 patients and thus has an evidence level of I. In patients with very good prognosis, chemotherapy can be foregone. As the first test of its kind, EndoPredict is offered directly by the local pathology as a medical service. The result can be available already after one day, allowing timely planning of further treatment steps. For further information please visit www.sividon.com or www.endopredict.com. Press Contact: End of Media Release Issuer: Sividon Diagnostics GmbH Key word(s): Health 07.06.2013 Dissemination of a Press Release, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
214791 07.06.2013 |